SPOTLIGHT: Proacta raises $35M in venture funds

San Diego-based Proacta has garnered $35 million in its second round of venture capital. Much of that money will be used to develop PR-104, a compound that is designed to kill cancer cells. "PR-104 has the potential to be less toxic and more potent than current therapies. In addition, PR-104 in combination with current chemotherapy and biologic regimens offers the promise of improving current cancer treatments." Clarus Ventures led the round. Release

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.